Later-Line Treatments for HER2-Positive Breast Cancer
(MedPage Today) -- Based on results from the DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd; Enhertu) became the preferred, guideline-supported, second-line therapy for HER2-positive…
Read the full articleYou might also wanna read
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Conditions : Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive; HR Positive Interventions : Drug: Trastuzumab deruxtecan; Drug
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Conditions : Colorectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum Interventions : Drug: Fam-Trastuzumab Deruxtecan-N
Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer
A phase 2 study published in Clinical Breast Cancer evaluated whether combining tucatinib with trastuzumab deruxtecan could improve outcomes
<![CDATA[Toxicity Management and Quality of Life Considerations for Patients with HER2-Positive Metastatic Breast Cancer]]>
<![CDATA[Practical Toxicity Monitoring and Multidisciplinary Management in HER2-Positive Metastatic Breast Cancer]]>
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
Conditions : Breast Cancer Interventions : Drug: BL-M07D1; Drug: DS-8201 Sponsors : Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Cheng
Comments
Sign in to join the conversation.
No comments yet. Be the first.